Smart scan may personalize esophageal cancer therapy

NCT ID NCT07385664

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether a special PET scan (FAPI-PET/CT) can help doctors choose the best treatment for people with resectable esophageal cancer. After two cycles of chemoimmunotherapy, the scan results will guide whether patients continue with more chemoimmunotherapy or switch to chemoradiation. The study aims to improve the chance of a complete response (no cancer left after treatment) and involves 66 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
chemoimmunotherapy and concurrent chemoradiotherapy
What this could lead to
If successful, this could lead to a more personalized treatment approach for esophageal cancer, potentially improving response rates and reducing unnecessary side effects.
What could go wrong
This is an early phase II trial with only 66 participants, so results may not apply to everyone. The approach is complex and may not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.